Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-05-11
2011-11-08
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C424S218100, C536S023720, C435S007100
Reexamination Certificate
active
08052974
ABSTRACT:
The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.
REFERENCES:
patent: 5494671 (1996-02-01), Lai et al.
patent: 5514375 (1996-05-01), Paoletti et al.
patent: 5696108 (1997-12-01), Heath, Jr. et al.
patent: 5744140 (1998-04-01), Paoletti et al.
patent: 5744141 (1998-04-01), Paoletti et al.
patent: 6184024 (2001-02-01), Lai et al.
patent: 6258788 (2001-07-01), Schmaljohn
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 6306899 (2001-10-01), Cheng et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6416763 (2002-07-01), McDonnel et al.
patent: 6432411 (2002-08-01), Ivy et al.
patent: 6455509 (2002-09-01), Kochel et al.
patent: 6685948 (2004-02-01), Zeng et al.
patent: 6875433 (2005-04-01), Hart et al.
patent: 6946125 (2005-09-01), Rahal
patent: 7074555 (2006-07-01), Esty et al.
patent: 7153513 (2006-12-01), Chu
patent: 7244430 (2007-07-01), Throsby et al.
patent: 7425437 (2008-09-01), Uytdehaag et al.
patent: 7491516 (2009-02-01), Collinson et al.
patent: 7537764 (2009-05-01), Throsby et al.
patent: 2003/0148261 (2003-08-01), Fikrig et al.
patent: 2004/0009178 (2004-01-01), Bowdish et al.
patent: 2004/0077086 (2004-04-01), Reiter et al.
patent: 2004/0197769 (2004-10-01), Wong et al.
patent: 2004/0258699 (2004-12-01), Bowdish et al.
patent: 2006/0057149 (2006-03-01), Johnson et al.
patent: 2006/0067940 (2006-03-01), Diamond et al.
patent: 2006/0115837 (2006-06-01), Fremont et al.
patent: 2006/0115896 (2006-06-01), Wong et al.
patent: 2006/0269571 (2006-11-01), Hall et al.
patent: 2007/0025992 (2007-02-01), Takayama et al.
patent: 2009/0017068 (2009-01-01), UytdeHaag et al.
patent: 2009/0054254 (2009-02-01), Throsby et al.
patent: 0 102 228 (1984-03-01), None
patent: 0 869 184 (1998-10-01), None
patent: 0 872 553 (1998-10-01), None
patent: 0 947 581 (1999-10-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 93/09872 (1993-05-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 99/26653 (1999-06-01), None
patent: WO 99/63095 (1999-12-01), None
patent: WO 00/10991 (2000-03-01), None
patent: WO 00/12128 (2000-03-01), None
patent: WO 00/14245 (2000-03-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/03729 (2001-01-01), None
patent: WO 01/38362 (2001-05-01), None
patent: WO 01/39802 (2001-06-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/60847 (2001-08-01), None
patent: WO 02/15664 (2002-02-01), None
patent: WO 02/072036 (2002-09-01), None
patent: WO 02/103012 (2002-12-01), None
patent: WO 2004/042042 (2004-05-01), None
patent: WO 2005/007800 (2005-01-01), None
patent: WO 2005/106483 (2005-11-01), None
patent: WO 2005/123774 (2005-12-01), None
patent: WO 2006/067122 (2006-06-01), None
Vogt et al., Journal of Virology, Jul. 2009, 83(13):6494-6507.
Ben-Nathan et al., BMC Infectious Diseases, 2009, vol. 9, No. 18, eight pages.
Bae et al., “Production of Hantaan Virus from Human Immortalized Retina Cell and Its Immunogenicity.” J. Microbiol. Biotechnol., Dec. 20, 2002, pp. 882-889, vol. 12, No. 6.
Blitvich et al., Epitope-Blocking Enzyme-Linked Immunosorbent Assays for the Detection of Serum Antibodies to West Nile Virus in Multiple Avian Species, Journal of Clinical Microbiology, Mar. 2003, pp. 1041-1047, vol. 41, No. 3.
Bao et al., “Flavivirus Induces MHC Antigen on Human Myoblasts: A Model of Autoimmune Myositis?” Muscle and Nerve. Nov. 1992, pp. 1271-1277, vol. 15, No. 11.
Boel et al., Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments, Journal of Immunological Methods, 2000, pp. 153-166, vol. 239.
Chen et al., Preparation of monoclonal antibodies against West Nile virus envelope protein domain. Chinese J. Exp. Clin Virol., Sep. 2006, pp. 213-215, vol. 20, No. 3, abstract only.
Chung et al., Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc gamma Receptor-Dependent and -Independent Mechanisms, Journal of Virology, Feb. 2006, pp. 1340-1351, vol. 80, No. 3.
Fields et al., Virology (Third Ed.), excerpt. pp. 931-932, 1996.
Gallimore et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, May 3, 1986, pp. 499-508. vol. 6, No. 3.
Goncalvez et al., Chimpanzee Fab Fragments and a Derived Humanized Immunoglobulin GI Antibody That Efficiently Cross-Neutralize Dengue Type 1 and Type 2 Viruses. Journal of Virology, Dec. 2004, pp. 12910-12918, vol. 78. No. 23.
Jia et al., “Genetic analysis of West Nile Virus New York 1999 encephalitis virus,” The Lancet, Dec. 4, 1999, pp. 1971-1972. vol. 354, No. 9196.
Leibl et al., “Adjuvant/carrier activity of inactivated tick-borne encephalitis virus.” Vaccine, 1998, pp. 340-345, vol. 16, No. 4.
Malkinson et al, “Use of Live and Inactivated Vaccines in the Control of West Nile Virus in Domestic Geese,” Annals of the New York Academy of Sciences, 2001, pp. 255-261.
Marks et al., By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling, Bio/Technology, Jul. 1992, pp. 779-783, vol. 10.
Mehlhop et al., Complement Activation Is Required for Induction of a Protective Antibody Response against West Nile Virus Infection, Journal of Virology. Jun. 2005. pp. 7466-7477, vol. 79, No. 12.
Niedrig et al., Monoclonal Antibodies Directed Against Tick-Borne Encephalitis Virus with Neutralizing Activity In Vivo, Acta virologica, 1994, pp. 141-149, vol. 38.
Nybakken et al., Structural basis of West Nile virus neutralization by a therapeutic antibody, Nature, Sep. 29, 2005, pp. 764-768, vol. 437.
Pau et al., “The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines,” Vaccine, 2001, pp. 2716-2721, vol. 19.
PCT International Preliminary Examination Report, PCT/EP2003/50806, dated Feb. 17, 2005.
PCT International Preliminary Report on Patentability, PCT/EP2006/063463, dated Sep. 10, 2007, 10 pages.
PCT International Search Report, PCT/EP2003/50806, dated Apr. 26, 2004.
PCT International Search Report, PCT/EP2006/063463, dated Oct. 6, 2006.
Razumov et al., Neutralizing Monoclonal Antibodies Against Russian Strain of the West Nile Virus, Viral Immunology, 2005, pp. 558-568, vol. 18, No. 3.
Roehrig et al., Antibody Prophylaxis and Therapy for Flavivirus Encephalitis Infections, Ann. N. Y. Acad. Sci., Dec. 2001, pp. 286-297, vol. 951.
Rudikoff et al., PNAS USA, 19082, 79:1979-1983.
Sanchez et al., Characterization of neutralizing antibodies to West Nile virus, Virology, 2005, pp. 70-82, vol. 336.
Shen et al., “Early Induction of Interferon-Independent Virus-Specific ICAM-I (CD54) Expression by Flavivirus in Quiescent but Not Proliferating Fibroblasts—Implications for Virus-Host Interactions,” Virology, 1995, pp. 437-449, vol. 208, No. 2.
Shi et al., “Infectious cDNA Clone of the Epidemic West Nile Virus from New York City,” J. of Virology, Jun. 2002, pp. 5847-5856, vol. 76, No. 12.
Yamshchikov et al., “An Infectious Clone of the West Nile Flavivirus,” Virology, Mar. 15, 2001, pp. 294-304, vol. 281, No. 2.
Burton D.R., et al., Human antibodies from combinatorial libraries, Adv. Immunol., 1994, pp. 191-280, vol. 57.
Clackson T., et al., Making antibody fragments using phage display libraries, Nature, 1991, pp. 624-628, vol. 352.
De Kruif J., et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci., 1995a, p. 3938, vol. 92.
De Kruif J., et al., Selection and application of human single-chain Fv antibody fragments from a semi-synthet
De Kruif Cornelis Adriaan
Throsby Mark
Chen Stacy B.
Crucell Holland B.V.
TraskBritt
LandOfFree
Host cell specific binding molecules capable of neutralizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Host cell specific binding molecules capable of neutralizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Host cell specific binding molecules capable of neutralizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291031